A vitamin D‐based strategy overcomes chemoresistance in prostate cancer
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16492 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Kateryna Len-Tayon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Genetics and Molecular and Cellular Biology (IGBMC), Illkirch-Graffenstaden, France. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Vitamin D, Docetaxel, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Canceropole Est, Ligue Contre le Cancer Est.
Abstract (Originalsprache)
Background and purpose Castration‐resistant prostate cancer (CRPC) is a common male malignancy that requires new therapeutic strategies due to acquired resistance to its first‐line treatment, docetaxel. The benefits of vitamin D on prostate cancer (PCa) progression have been previously reported. This study aimed to investigate the effects of vitamin D on chemoresistance in CRPC. Experimental approach Structure function relationships of potent vitamin D analogues were determined. The combination of the most potent analogue and docetaxel was explored in chemoresistant primary PCa spheroids and in a xenograft mouse model derived from a patient with a chemoresistant CRPC. Key results Here, we show that Xe4MeCF3 is more potent than the natural ligand to induce vitamin D receptor (VDR) transcriptional activities and that it has a larger therapeutic window. Moreover, we demonstrate that VDR agonists restore docetaxel sensitivity in PCa spheroids. Importantly, Xe4MeCF3 reduces tumour growth in a chemoresistant CRPC patient‐derived xenograft. In addition, this treatment targets signalling pathways associated with cancer progression in the remaining cells. Conclusion and implications Taken together, these results unravel the potency of VDR agonists to overcome chemoresistance in CRPC and open new avenues for the clinical management of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Genetics and Molecular and Cellular Biology (IGBMC), Illkirch-Graffenstaden, France.
- CNRS UMR 7104, Illkirch-Graffenstaden, France.
- Inserm U1258, Illkirch-Graffenstaden, France.
- University of Strasbourg, Illkirch-Graffenstaden, France.
- Urosphere, Toulouse, France.
- Transgene SA, Illkirch-Graffenstaden, France.
ORCID-Profile: Kateryna Len-Tayon, Gilles Laverny
Förderung
- Agence Nationale de la Recherche
- Canceropole Est
- Ligue Contre le Cancer Est
- SATT Conectus
- Association pour La Recherche sur les Tumeurs Prostatiques (ARTP)
- Institut National du Cancer
- Ministry of Higher Education and Research
- Fondation ARC pour la Recherche sur le Cancer
Zitieren
APA
Len-Tayon, K., Beraud, C., Fauveau, C., Belorusova, A. Y., Chebaro, Y., Mouriño, A., Massfelder, T., Chauchereau, A., Metzger, D., Rochel, N., & Laverny, G. (2024). A vitamin D‐based strategy overcomes chemoresistance in prostate cancer. British Journal of Pharmacology. https://doi.org/10.1111/bph.16492
Vancouver
Len-Tayon K, Beraud C, Fauveau C, Belorusova AY, Chebaro Y, Mouriño A, et al. A vitamin D‐based strategy overcomes chemoresistance in prostate cancer. British Journal of Pharmacology. 2024. doi:10.1111/bph.16492
BibTeX
@article{LenTayon2024,
author = {Len-Tayon, Kateryna and Beraud, Claire and Fauveau, Clara and Belorusova, Anna Y and Chebaro, Yassmine and Mouriño, Antonio and Massfelder, Thierry and Chauchereau, Anne and Metzger, Daniel and Rochel, Natacha and Laverny, Gilles},
title = {A vitamin D‐based strategy overcomes chemoresistance in prostate cancer},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16492}
}
EUVIMED